ShiLai™ Healthcare — Peptide Manufacturer & Retatrutide OEM
Biomaterial Development Platform

Advanced Hemostatic Biomaterials

Collagen · Chitosan · Composite Scaffolds · Lyophilization

Development and manufacturing of absorbable porous hemostatic materials based on collagen and composite biomaterial platforms. From material formulation and prototype development to freeze-drying, testing and OEM manufacturing.

Technology Platforms

Three biomaterial development platforms at different stages of development.

01Established Platform

Collagen Hemostatic Sponge

A porous collagen-based biomaterial platform developed around controlled scaffold architecture, fluid uptake and material interaction at the bleeding interface.

  • Porous Collagen Scaffold
  • Fluid Uptake
  • Platelet Interaction
  • Lyophilized Structure
Explore Collagen Platform
02Next-Generation Platform

Collagen–Chitosan Composite

A composite biomaterial development platform combining collagen and chitosan to explore rapid fluid uptake, scaffold performance and improved structural integrity.

  • Composite Biomaterial
  • Rapid Fluid Uptake
  • Porous Architecture
  • Structural Integrity
Explore Composite Platform
03Development Platform

Advanced Wet-Adhesive Hemostat

An exploratory biomaterial platform focused on next-generation wet-interface adhesion and advanced hemostatic material architectures.

  • Development Platform
  • Future IP Direction
  • Advanced Biomaterials
Discuss Development

Lyophilization Technology for Porous Biomaterials

Freeze-drying is a core process within our porous biomaterial development platform, enabling controlled scaffold formation and optimization of material architecture.

01

Formulation

02

Casting

03

Controlled Freezing

04

Lyophilization

05

Porous Scaffold

06

Testing

1
Formulation
2
Casting
3
Controlled Freezing
4
Lyophilization
5
Porous Scaffold
6
Testing

Development & Manufacturing Capabilities

End-to-end capabilities from material formulation to OEM production.

Material Formulation

Collagen and composite biomaterial formulation development.

Scaffold Architecture

Controlled porous scaffold design and optimization.

Lyophilization

Freeze-drying process development for porous biomaterials.

Prototype Development

From concept to characterized prototype.

Testing & Characterization

Material testing and analytical characterization.

OEM Manufacturing

Scale-up and OEM production for qualified B2B partners.

From Peptide Lyophilization to Advanced Biomaterials

ShiLai™ is extending its formulation, freeze-drying and analytical capabilities into porous biomaterial development, creating a platform for collagen-based and composite hemostatic materials. The same lyophilization infrastructure and analytical testing capabilities that support our peptide manufacturing platform are applied to biomaterial scaffold development.

Frequently Asked Questions

What hemostatic biomaterial platforms does ShiLai™ develop?

ShiLai™ develops collagen-based porous hemostatic sponge platforms and collagen–chitosan composite biomaterial platforms, with advanced wet-adhesive hemostat architectures under exploratory development.

Does ShiLai™ offer OEM manufacturing for hemostatic sponges?

Yes. ShiLai™ supports qualified B2B partners with custom development, prototype production, lyophilization, testing and scale-up manufacturing for collagen and composite hemostatic biomaterials.

What is the development stage of these hemostatic materials?

These are development-stage biomaterial platforms. ShiLai™ does not claim FDA clearance, CE marking or clinical validation unless specifically documented for a given product.

Can ShiLai™ develop custom dimensions and compositions?

Yes. Custom composition, dimensions, porosity parameters and packaging can be discussed for qualified B2B development projects. Contact our team to discuss your project requirements.

Discuss Your Hemostatic Biomaterial Project

Contact our development team to discuss material platforms, prototype requirements, testing and OEM manufacturing for your project.